Oakworth Capital Inc. Purchases 1,452 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Oakworth Capital Inc. grew its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 15.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,127 shares of the company’s stock after buying an additional 1,452 shares during the quarter. Oakworth Capital Inc.’s holdings in Harmony Biosciences were worth $383,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in shares of Harmony Biosciences by 51.6% during the second quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock valued at $9,275,000 after purchasing an additional 104,691 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Harmony Biosciences by 244.4% during the third quarter. SG Americas Securities LLC now owns 15,724 shares of the company’s stock valued at $629,000 after purchasing an additional 11,158 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Harmony Biosciences by 15.3% during the third quarter. Handelsbanken Fonder AB now owns 11,300 shares of the company’s stock valued at $452,000 after purchasing an additional 1,500 shares during the last quarter. CWM LLC grew its stake in shares of Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt grew its stake in shares of Harmony Biosciences by 84.8% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 44,900 shares of the company’s stock valued at $1,796,000 after purchasing an additional 20,600 shares during the last quarter. 86.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Sandip Kapadia sold 1,775 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey Dierks sold 1,123 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock worth $2,831,679 over the last ninety days. Company insiders own 30.80% of the company’s stock.

Wall Street Analyst Weigh In

HRMY has been the topic of a number of recent research reports. Cantor Fitzgerald raised their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Raymond James reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Harmony Biosciences in a report on Monday, January 27th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $55.00.

Harmony Biosciences Trading Up 1.0 %

Shares of NASDAQ:HRMY opened at $39.36 on Thursday. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The company’s fifty day simple moving average is $35.66 and its 200 day simple moving average is $35.42. The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 0.51 and a beta of 0.80.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.